Axsome Second Quarter Financial Results

Axsome Therapeutics released impressive second quarter results this morning. The biggest positive was that ADVANCE 2 for Alzheimer's Agitation, is to be released second half of 2024. 

• Auvelity for MDD sales totaled $65 million for the quarter
• A New Drug Application for AXS-07 has been submitted
• Alzheimer's Agitation phase 3, to be released 2nd half 2024
• ADHD phase 3 clinical trial results, 2nd half 2024

The stock had a wild day due to overall market volatility, recording a low of 72.21 early, but closed at 83.21 end of day, outperforming the broader market sell-off. Thank you for reading.

Axsome Fourth Quarter Financial Results

Axsome released their fourth quarter financial results today. Just a few highlights from the just completed impressive quarter, are below. 

• Auvelity for MDD sales totaled $49.0 million for the quarter
• Sunosi for narcolepsy sales totaled $22.5 million for the quarter
• $386 million in cash on hand, end of quarter
• AXS-12 clinical trial for cataplexy, to read out in the first quarter, 2024
• AXS-05 clinical trial for Alzheimer's Disease Agitation, second half 2024

The only negative seen for this quarterly release is the clinical trial of AXS-05 for Alzheimer's Disease Agitation, which has been moved to be released in the second half of 2024.  Current chart of Axsome below. Thank you for reading.

Axsome 3rd Quarter Financial Results

Axsome released their third quarter financial results on Monday. Just a few highlights from the just completed impressive quarter, are below. 

• Auvelity for MDD sales totaled $37.7 million for the quarter
• Sunosi for narcolepsy sales totaled $20.1 million for the quarter
• $417 million in cash on hand, end of quarter
• AXS-12 clinical trial for cataplexy, to read out in the first quarter, 2024
• AXS-05 clinical trial for Alzheimer's Disease Agitation, complete first half of 2024

Below is up to date, weekly prescriptions of Auvelity for MDD. Thank you for reading.

      

Axsome 1st Quarter 2023 Financial Results

Axsome released their first quarter financial results on Monday May 8th. Just a few highlights from the just completed impressive quarter, are below. 

• Auvelity for MDD sales totaled $15.7 million for the quarter
• Sunosi for narcolepsy sales totaled $12.9 million for the quarter
• $246 million in cash on hand, end of quarter
• AXS-12 clinical trial for cataplexy, to read out in the second quarter

Axsome's share price has been moving steadily higher the past couple weeks. Below is a monthly chart of AXSM stock, which has just closed at it's highest level seen in the past two years. Thank you for reading.